NCT07673081
Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic Cosmos
At risk: Primary completion moved at least 4 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Primary and study completion pushed from Sep 30, 2026 to Jan 31, 2027
- Minor Trial status changed: Not Yet Recruiting → Active, Not Recruiting
- Primary and study completion moved earlier from Nov 30, 2026 to Sep 30, 2026
- Study sites: 0 to 1
- Start date changed from estimate of Jun 20, 2026 to Jun 22, 2026
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Incidence of RSV-related Acute Respiratory Infection (ARI) hospitalization
Timeframe: up to 3 years
Incidence of RSV-related Lower Respiratory Tract Disease (LRTD) hospitalization
Timeframe: up to 3 years
Secondary (2)
Incidence of RSV-related outcomes
Incidence of All-cause outcomes
Arms and interventions
Vaccinated group
Individuals with documented receipt of an RSV vaccine in EHR data. Vaccines included: ABRYSVO® (Pfizer),AREXVY® (GSK), mRESVIA® (Moderna)
Unvaccinated comparator group:
Individuals not yet vaccinated at cohort entry, but otherwise eligible
Sites
1 site in 1 country
- PfizerNew York, New York, United States